1.Alternative Name：Siglec-2；B-cell receptor CD22; BL-CAM; B-lymphocyte cell adhesion molecule; CD22 antigenMGC130020; CD22 molecule; CD22; sialic acid binding Ig-like lectin 2; Sialic acid-binding Ig-like lectin 2; Siglec2; Siglec-2; SIGLEC2FLJ22814; T-cell surface antigen Leu-14
2.Target：CD22
3.Source：Human CD22 was expressed from HEK293 with human IgG1 FC at the C-terminal
4.Sequence：Thr21-Ile192
5.Protein structure:：P20273hFC
6.Molecular Characterization:The protein has a calculated MW of 101kDa.The reducing (R) heterodimer protein migrates as 130-150 kDa due to glycosylation
7.Purity:SDS-PAGE>95%
8.Reconstitution:sterile H2O
9.Endotoxin:<1EU/mg
10Formulation:Lyophilized from 0.22 μm filtered solution in PBS, pH7.4.
11.SDS-PAGE

Determined by SDS-PAGE, the purity of the protein is greater than 95%.

12.ELISA

When Recombinant Human CD22/ hFC Protein is immobilized at 2μg/mL (100 μL/well), the concentration of Anti-Human CD22(pinatuzumab) that produces 50% of the optimal binding response is approximately 60 ng/ml.

14.Note:For Research Use Only.